1 May 2004
BOXMEER (The Netherlands)
Boxmeer, May 2004 – Intervet International bv, the animal health business of Akzo Nobel, has set up a new Award to encourage scientists or life science research institutions to work in research areas that serve the 3R-concept i.e. reducing, refining or replacing the use of animals in testing for development and production of veterinary medicines.
The award, worth € 20,000, will be given annually to scientists or institutions that have delivered excellent contributions to the 3R's for the development and production of veterinary medicinal products, documented by a publication in the last two years. The scope is covering in vitro models used in R&D replacing animal testing for licensing purposes as well as studies avoiding using animals in efficacy, safety and quality testing in the production of biologicals and pharmaceuticals for animals.
Intervet would like to see the scope interpreted as broadly as possible. It can cover, for example, residue testing, new toxicological methods, challenging test replacements, epidemiological studies focusing on the correlation of field data and protection of animals by vaccination, new epitope identification, genomics, proteomics, alternatives to production methods using animal by-products or animals.
The applications will be screened by Intervet at country level supported by a selection team consisting of an Intervet representative, a clinician and a public research center representative. The judgment laid down in an expert report will form the basis for the final selection of candidates from the different regions.
The award is named after Dieter Lütticken. Dieter Lütticken, committed to research in microbiology and virology, contributed to Intervet research and development for more than a quarter of a century. With his ambition, creativity and broad knowledge in basic and applied science he guided and shaped Intervet's R&D for many years. He established what became tradition – Intervet's sound support and close collaboration with basic research. Dieter Lütticken retired in June 2003 from his position as Vice President and Intervet's Head of R&D.
Intervet will actively screen at country level under participation of representative clinics and public research centers in the regions Europe, North-America, Australia and Japan for candidates from all life-science research institutions. Private enterprises are excluded. This year’s deadline is September 30, 2004. The award will be first granted in 2005.
